Pneumococcal Polysaccharide Vaccination in Pediatric Inflammatory Bowel Disease
According to current recommendations, in addition to 13-valent pneumococcal conjugate vaccine (PCV13) series, all children with inflammatory bowel disease (IBD) aged ≥2 years, with planned or current immunosuppression, should receive pneumococcal polysaccharide vaccine (PPSV23). The primary aim was...
Main Authors: | Tsega Temtem MD, John Whitworth MD, Bindiya Bagga MD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-05-01
|
Series: | Global Pediatric Health |
Online Access: | https://doi.org/10.1177/2333794X19849754 |
Similar Items
-
Weekly Folic Acid Is a Convenient and Well-Tolerated Alternative to Daily Dosing in Pediatric Patients with Inflammatory Bowel Disease on Methotrexate
by: Tsega Adera Temtem, et al.
Published: (2023-03-01) -
The effect of age on the response to the pneumococcal polysaccharide vaccine
by: Nahm Moon H, et al.
Published: (2010-03-01) -
Immunogenicity, safety and efficacy of 23-valent pneumococcal polysaccharide vaccine in patients with inflammatory joint diseases (preliminary data)
by: M. M. Baranova, et al.
Published: (2021-08-01) -
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
by: James T. Peterson, et al.
Published: (2019-03-01) -
Pediatric Invasive Pneumococcal Disease (IPD) in Yogyakarta, Indonesia: A Case Series
by: Eggi Arguni MD, PhD, et al.
Published: (2022-06-01)